Prescillia Forey, Emeline Cros-Perrial, Charles Dumontet and Lars Petter Jordheim* Pages 4088 - 4116 ( 29 )
Nucleotide metabolism has been targeted for many years and in various clinical settings, including cancer. The increased knowledge of certain enzymes involved in this metabolism and associated cellular processes accumulated over the last few years, gives important information related to the druggability of certain proteins and the use of inhibitors for others. Here, we review recent data on such enzymes with a major interest in drug development, i.e. SAMHD1 and the proteins of the NUDIX family. These include information on their roles in cancer progression, correlations with clinical outcomes in cancer patients, and the development and study of enzymatic inhibitors.
NUDIX, MTH1, SAMHD1, cancer, treatment, inhibitors.
Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancerologie de Lyon, Lyon, 69008, Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancerologie de Lyon, Lyon, 69008, Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancerologie de Lyon, Lyon, 69008, Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancerologie de Lyon, Lyon, 69008